Since inhibition of β2-M results in iron overload, increase in reactive oxygen species and decreases in stress response proteins in vitro, we tested if treatment with anti-β2-M Ab could sensitize prostate cancer cells to clinically used chemotherapeutic agents. The gene discussed is B2M; the disease is prostate carcinoma.